OXFORD - Arrow Therapeutics has pooled several technologies to discover and develop anti-infectives, combining expertise in target discovery, assay development, small molecule chemical libraries, medicinal chemistry for lead optimization and preclinical development. Ultimately, Arrow hopes that its array of skills and collaborations will enable it to generate lead compounds in six months, compared to an industry average it estimates to be three times as long.

CEO Ken Powell believes this combination of skills is what has led to the company's first clinical development deal, announced last week, with Triangle Pharmaceuticals Inc. (VIRS, Durham, N.C.).